Last update Aug. 6, 2021

Λατανοπρόστη

Compatible

Safe substance and/or breastfeeding is the best option.

Synthetic analog of dinoprost (prostaglandin F2-alpha).
Indicated in the treatment of ocular hypertension and glaucoma.
Topical administration in the form of eye drops, one drop a day.

At the date of the last update, the authors did not find published data on its excretion in breast milk.

Its pharmacokinetic data (moderately high molecular weight, high percentage of protein binding, very short half-life and high pKa) make it unlikely that significant amounts will pass into breast milk (Belkin 2020, Blumen 2020).

Its null oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.

The absorption should be minimized by pressing the tear duct (inner corner of the eye) with the finger for 1 to 5 minutes and administering the dose immediately after a breastfeed (Belkin 2020, Méndez 2012).

Alternatives

  • Acetazolamide (Safe substance and/or breastfeeding is the best option.)
  • Timolol Maleate (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Λατανοπρόστη is Latanoprost in Greek.

Is written in other languages:

Group

Λατανοπρόστη belongs to this group or family:

Tradenames

Main tradenames from several countries containing Λατανοπρόστη in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 433 daltons
Protein Binding 90 %
VD 0.16 l/Kg
pKa 14.47 -
Tmax 0.1 hours
T½ 0.3 hours

References

  1. Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM; American Glaucoma Society and the Canadian Glaucoma Society.. A Practical Guide to the Pregnant and Breastfeeding Patient with Glaucoma. Ophthalmol Glaucoma. 2020 Mar - Apr;3(2):79-89. Abstract
  2. Mann. Latanoprost. Ficha técnica. 2020 Full text (in our servers)
  3. Blumen-Ohana E, Sellem E. [Pregnancy & glaucoma: SFO-SFG recommendations]. J Fr Ophtalmol. 2020 Jan;43(1):63-66. Abstract
  4. Sandoz. Latanoprost. Drug Summary. 2017 Full text (in our servers)
  5. Méndez-Hernández C. Uso de fármacos antiglaucomatosos durante el embarazo y lactancia. [Use of glaucoma medications during pregnancy and breastfeeding]. Arch Soc Esp Oftalmol. 2012 Dec;87(12):389-91. Abstract

Total visits

950

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM